RightFit
RecruitingPhase not listed

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
0 Years and older
Sex
Female only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at the health of pregnant women with migraine and their babies through 12 months of age. It includes women who took rimegepant during or just before pregnancy and women who did not take it.

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Pregnant women diagnosed with migraine who took at least 1 dose of rimegepant during pregnancy or within 3 days before becoming pregnant.
  • Pregnant women diagnosed with migraine who never took rimegepant before or during pregnancy.

Who can't join

  • Women who used certain other migraine medicines during or just before pregnancy: other CGRP blockers (such as ubrogepant), CGRP antibodies, or ditans (such as lasmiditan). These are types of migraine medicines.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception) * Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy Exclusion Criteria: • Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy

Study sites (1)

NC